Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry D Anderson

Showing results (31-40 of 114) with videos related to

Pageof 12
Sort By:
Haematologica|March 17, 2018
Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-<i>versus</i>-lymphoma effectEnrico Maffini, Larry D Anderson, Brenda M Sandmaier, et al.
British Journal of Haematology|March 17, 2026
Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologistsRahul Banerjee, Sharlene Dong, Georgia McCaughan, et al.
American Journal of Clinical Pathology|September 4, 2020
Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique EntitySharon Koorse Germans, Ozlem Kulak, Prasad Koduru, et al.
Blood Cancer Journal|March 23, 2024
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysisFieke W Hoff, Rahul Banerjee, Adeel M Khan, et al.
Bone Marrow Transplantation|September 6, 2023
Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United StatesMingqian Lin, Noel Estrada-Merly, Mary Eapen, et al.
Frontiers in Health Services|May 9, 2024
Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy groupJay R Hydren, Dee Lin, Nathan W Sweeney, et al.
Blood Cancer Journal|March 29, 2025
Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysisSharlene Dong, Rahul Banerjee, Adeel M Khan, et al.
Leukemia Research|March 30, 2021
Corrigendum to "The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement" [Leukemia Res. 100 (2021) 106480]Colin P Bergstrom, Saurabh Dahiya, Weina Chen, et al.
Transplantation and Cellular Therapy|November 11, 2023
Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyOlalekan O Oluwole, Bhagirathbhai Dholaria, Tristan E Knight, et al.
JAMA Oncology|July 21, 2022
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted StudyBenjamin A Derman, Ankit Kansagra, Jeffrey Zonder, et al.
Pageof 12

Showing results (31-40 of 114) with videos related to

Sort By:
Pageof 12
Haematologica|March 17, 2018
Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-<i>versus</i>-lymphoma effectEnrico Maffini, Larry D Anderson, Brenda M Sandmaier, et al.
British Journal of Haematology|March 17, 2026
Preferred standard-of-care carfilzomib dosing in multiple myeloma: An international survey of haematologists/oncologistsRahul Banerjee, Sharlene Dong, Georgia McCaughan, et al.
American Journal of Clinical Pathology|September 4, 2020
Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique EntitySharon Koorse Germans, Ozlem Kulak, Prasad Koduru, et al.
Blood Cancer Journal|March 23, 2024
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysisFieke W Hoff, Rahul Banerjee, Adeel M Khan, et al.
Bone Marrow Transplantation|September 6, 2023
Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United StatesMingqian Lin, Noel Estrada-Merly, Mary Eapen, et al.
Frontiers in Health Services|May 9, 2024
Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy groupJay R Hydren, Dee Lin, Nathan W Sweeney, et al.
Blood Cancer Journal|March 29, 2025
Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysisSharlene Dong, Rahul Banerjee, Adeel M Khan, et al.
Leukemia Research|March 30, 2021
Corrigendum to "The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement" [Leukemia Res. 100 (2021) 106480]Colin P Bergstrom, Saurabh Dahiya, Weina Chen, et al.
Transplantation and Cellular Therapy|November 11, 2023
Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular TherapyOlalekan O Oluwole, Bhagirathbhai Dholaria, Tristan E Knight, et al.
JAMA Oncology|July 21, 2022
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted StudyBenjamin A Derman, Ankit Kansagra, Jeffrey Zonder, et al.
Pageof 12